Broker Center sponsored links

Perrigo gets FDA nod for generic Penlac nail-fungus treatment

Wed Sep 19, 2007 2:48pm EDT
 
Email | Print | | Reprints | Single Page
[-] Text [+]

Sept 19 (Reuters) - Perrigo Co (PRGO.O: Quote, Profile, Research, Stock Buzz) said it received final approval from U.S. health regulators for Ciclopirox topical solution, a generic version of Sanofi-Aventis' (SASY.PA: Quote, Profile, Research, Stock Buzz) Penlac nail-fungus treatment.

The generic drugmaker said brand sales for Penlac for the last 12 months ending August were $92 million, citing data from publisher Wolters Kluwer. (Reporting by Neha Pathania in Bangalore)

 

Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.

Have a correction to this article? Email the editors

Featured Broker sponsored link

Editor's Choice

Photo

A selection of our best photos from the past 24 hours.  View Slideshow 

Most Popular on Reuters